Am J Perinatol 2015; 32(14): 1324-1330
DOI: 10.1055/s-0035-1564426
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections of Insulin for the Management of Type 1 Diabetes Mellitus in Pregnancy: Association with Neonatal Chemical Hypoglycemia

James A. Sargent
1   Department of Reproductive Medicine, UC San Diego, San Diego, California
,
Hilary A. Roeder
1   Department of Reproductive Medicine, UC San Diego, San Diego, California
,
Kristy K. Ward
2   Department of Gynecologic Oncology, University of Florida, Jacksonville, Florida
,
Thomas R. Moore
1   Department of Reproductive Medicine, UC San Diego, San Diego, California
,
Gladys A. Ramos
1   Department of Reproductive Medicine, UC San Diego, San Diego, California
› Author Affiliations
Further Information

Publication History

22 July 2015

05 August 2015

Publication Date:
13 October 2015 (online)

Abstract

Objective We hypothesized that patients with type 1 diabetes mellitus (T1DM) who were managed during their pregnancy with a continuous subcutaneous insulin infusion (CSII) would have a lower incidence of neonatal hypoglycemia (NH) than patients managed with multiple daily injections (MDI) of insulin.

Study Design This was a retrospective cohort of 95 women with T1DM who delivered singleton, term neonates between 2007 and 2014. The primary outcome was incidence of NH (capillary plasma glucose ≤ 45 mg/dL) in the first 24 hours after birth.

Results The incidence of NH was 66.0% (62/95). The NH rate was significantly higher in women managed with CSII versus MDI (62 vs. 38%, p = 0.024). Neonates with NH had a higher birth weight (3,867 ± 658 vs. 3,414 ± 619 g, p = 0.002). When analyzing intrapartum glucose management, mothers of neonates with NH had significantly less time managed on an insulin infusion (median interquartile range 7 [3.5–30.5] vs. 17.5 [2.0–17.5] hours, p = 0.014). In multivariable analysis, only maternal body mass index (BMI) (p = 0.035) and time on an insulin infusion (p = 0.043) were significantly associated with NH.

Conclusion In our population of patients with T1DM, CSII was more prevalent in the NH group; however, when controlling for other factors, intrapartum glucose management and early maternal BMI were the only variables associated with NH.

Notes

This study was approved by the UCSD Human Research and Protections Program, IRB# 111310. The findings in this article were presented as a poster at the 35th Annual Meeting, The Pregnancy Meeting, San Diego, CA, February 2–7, 2015.


 
  • References

  • 1 Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am 2010; 39 (3) 481-497
  • 2 Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011
  • 3 American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 60: Clinical Management Guidelines for Obstetrician-Gynecologists: pregestational diabetes mellitus. Obstet Gynecol 2005; 105: 675-685
  • 4 Buchanan TA, Kitzmiller JL. Metabolic interactions of diabetes and pregnancy. Annu Rev Med 1994; 45: 245-260
  • 5 Philips AF, Dubin JW, Matty PJ, Raye JR. Arterial hypoxemia and hyperinsulinemia in the chronically hyperglycemic fetal lamb. Pediatr Res 1982; 16 (8) 653-658
  • 6 Nold JL, Georgieff MK. Infants of diabetic mothers. Pediatr Clin North Am 2004; 51 (3) 619-637 , viii
  • 7 Widness JA, Teramo KA, Clemons GK , et al. Temporal response of immunoreactive erythropoietin to acute hypoxemia in fetal sheep. Pediatr Res 1986; 20 (1) 15-19
  • 8 Adamkin DH ; Committee on Fetus and Newborn. Postnatal glucose homeostasis in late-preterm and term infants. Pediatrics 2011; 127 (3) 575-579
  • 9 Cornblath M, Hawdon JM, Williams AF , et al. Controversies regarding definition of neonatal hypoglycemia: suggested operational thresholds. Pediatrics 2000; 105 (5) 1141-1145
  • 10 Cordero L, Treuer SH, Landon MB, Gabbe SG. Management of infants of diabetic mothers. Arch Pediatr Adolesc Med 1998; 152 (3) 249-254
  • 11 Cowett RM, Susa JB, Giletti B, Oh W, Schwartz R. Glucose kinetics in infants of diabetic mothers. Am J Obstet Gynecol 1983; 146 (7) 781-786
  • 12 Aucott SW, Williams TG, Hertz RH, Kalhan SC. Rigorous management of insulin-dependent diabetes mellitus during pregnancy. Acta Diabetol 1994; 31 (3) 126-129
  • 13 Wollitzer AD, Zisser H, Jovanovic L. Insulin pumps and their use in pregnancy. Diabetes Technol Ther 2010; 12 (Suppl. 01) S33-S36
  • 14 Pickup JC, Keen H, Parsons JA, Alberti KG, Rowe AS. Continuous subcutaneous insulin infusion: improved blood-glucose and intermediary-metabolite control in diabetics. Lancet 1979; 1 (8129) 1255-1257
  • 15 Lenhard MJ, Reeves GD. Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch Intern Med 2001; 161 (19) 2293-2300
  • 16 Mukhopadhyay A, Farrell T, Fraser RB, Ola B. Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials. Am J Obstet Gynecol 2007; 197 (5) 447-456
  • 17 Farrar D, Tuffnell DJ, West J. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev 2007; (3) CD005542
  • 18 Gabbe SG, Holing E, Temple P, Brown ZA. Benefits, risks, costs, and patient satisfaction associated with insulin pump therapy for the pregnancy complicated by type 1 diabetes mellitus. Am J Obstet Gynecol 2000; 182 (6) 1283-1291
  • 19 Petrovski G, Dimitrovski C, Bogoev M, Milenkovic T, Ahmeti I, Bitovska I. Is there a difference in pregnancy and glycemic outcome in patients with type 1 diabetes on insulin pump with constant or intermittent glucose monitoring? A pilot study. Diabetes Technol Ther 2011; 13 (11) 1109-1113
  • 20 Combs CA. Continuous glucose monitoring and insulin pump therapy for diabetes in pregnancy. J Matern Fetal Neonatal Med 2012; 25 (10) 2025-2027
  • 21 Kernaghan D, Farrell T, Hammond P, Owen P. Fetal growth in women managed with insulin pump therapy compared to conventional insulin. Eur J Obstet Gynecol Reprod Biol 2008; 137 (1) 47-49
  • 22 Grunberger G, Bailey TS, Cohen AJ , et al; AACE Insulin Pump Management Task Force. Statement by the American Association of Clinical Endocrinologists Consensus Panel on insulin pump management. Endocr Pract 2010; 16 (5) 746-762
  • 23 Misso ML, Egberts KJ, Page M, O'Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 2010; (1) CD005103
  • 24 Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002; 324 (7339) 705
  • 25 Bruttomesso D, Bonomo M, Costa S , et al; Italian Group for Continuous Subcutaneous Insulin Infusion in Pregnancy. Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or with insulin glargine and multiple daily injections of rapid-acting insulin analogues (glargine-MDI). Diabetes Metab 2011; 37 (5) 426-431
  • 26 Talaviya PA, Saboo BD, Joshi SR , et al. Pregnancy outcome and glycemic control in women with type 1 diabetes: a retrospective comparison between CSII and MDI treatment. Diabetes Metab Syndr 2013; 7 (2) 68-71
  • 27 Chen R, Ben-Haroush A, Weismann-Brenner A, Melamed N, Hod M, Yogev Y. Level of glycemic control and pregnancy outcome in type 1 diabetes: a comparison between multiple daily insulin injections and continuous subcutaneous insulin infusions. Am J Obstet Gynecol 2007; 197 (4) 404.e1-404.e5
  • 28 Cypryk K, Kosiński M, Kamińska P, Kozdraj T, Lewiński A. Diabetes control and pregnancy outcomes in women with type 1 diabetes treated during pregnancy with continuous subcutaneous insulin infusion or multiple daily insulin injections. Pol Arch Med Wewn 2008; 118 (6) 339-344
  • 29 Lepercq J, Abbou H, Agostini C , et al. A standardized protocol to achieve normoglycaemia during labour and delivery in women with type 1 diabetes. Diabetes Metab 2008; 34 (1) 33-37
  • 30 Kline GA, Edwards A. Antepartum and intra-partum insulin management of type 1 and type 2 diabetic women: impact on clinically significant neonatal hypoglycemia. Diabetes Res Clin Pract 2007; 77 (2) 223-230
  • 31 Ryan EA, Al-Agha R. Glucose control during labor and delivery. Curr Diab Rep 2014; 14 (1) 450
  • 32 Carron Brown S, Kyne-Grzebalski D, Mwangi B, Taylor R. Effect of management policy upon 120 Type 1 diabetic pregnancies: policy decisions in practice. Diabet Med 1999; 16 (7) 573-578
  • 33 Barrett HL, Morris J, McElduff A. Watchful waiting: a management protocol for maternal glycaemia in the peripartum period. Aust N Z J Obstet Gynaecol 2009; 49 (2) 162-167
  • 34 Williams AF. Hypoglycaemia of the newborn: a review. Bull World Health Organ 1997; 75 (3) 261-290